Evidence map›Paper›PMID 30662826›Full record

ArticleMedical mycology case reports2019

Azole resistance of

Martina Angileri, Mario Pasquetti, Michela De Lucia, Andrea Peano

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medical mycology case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Antifungal Effects ofPathogens (Basel, Switzerland) · 2026
    Article
  3. Global transcriptomic response ofFrontiers in veterinary science · 2026
    Article
  4. Article
  5. Antifungal Susceptibility ofAntibiotics (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Anti-Heliyon · 2024
    Article
  12. Article
  13. Article
  14. The Canadian veterinary journal = La revue veterinaire canadienne · 2023
    Article
  15. In Vitro Assessment of Azole and Amphotericin B Susceptibilities ofJournal of fungi (Basel, Switzerland) · 2022
    Article
  16. InvasiveCase reports in infectious diseases · 2022
    Article
  17. Article
  18. Azole resistance mechanisms in pathogenicAntimicrobial agents and chemotherapy · 2021
    Article
  19. Article
  20. In Vitro Azole and Amphotericin B Susceptibilities ofAntibiotics (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Martina AngileriSan Marco Veterinary Clinic, Via dell'Industria 3, 35030 Veggiano, Italy.
Mario PasquettiDipartimento di Scienze Veterinarie, Università di Torino, Largo Paolo Braccini 2, 10095 Grugliasco, Italy.
Michela De LuciaSan Marco Veterinary Clinic, Via dell'Industria 3, 35030 Veggiano, Italy.
Andrea PeanoDipartimento di Scienze Veterinarie, Università di Torino, Largo Paolo Braccini 2, 10095 Grugliasco, Italy.
University of Turin · ITVeterinary Oncological Center · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 5-year-old neutered female toy Poodle chronically treated with systemic and topical azoles to control recurrent Malassezia dermatitis/otitis was presented because of the loss of treatment efficacy. Minimum Inhibitory Concentrations (MICs) obtained in vitro for various azoles (especially itraconazole and ketoconazole) against Malassezia strains isolated from the dog were increased by several-fold compared with MICs obtained for control isolates. These results reinforced the assumption based on clinical observation, i.e. the development of azole resistance.

Indexed as

AzolesDogMalassezia pachydermatisResistance

Identifiers

PMID30662826
PMCPMC6325069
OpenAlexW2906629744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.